Advanced genetic engineering to achieve in vivo targeting of adenovirus utilizing camelid single domain antibody
For the developing field of gene therapy the successful address of the basic requirement effective gene delivery has remained a critical barrier. In this regard, the “Holy Grail” vector envisioned by the field's pioneers embodied the ability to achieve efficient and specific in vivo gene delive...
Gespeichert in:
| Veröffentlicht in: | Journal of controlled release 2021-06, Vol.334, p.106-113 |
|---|---|
| Hauptverfasser: | , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 113 |
|---|---|
| container_issue | |
| container_start_page | 106 |
| container_title | Journal of controlled release |
| container_volume | 334 |
| creator | Lee, Myungeun Lu, Zhi Hong Shoemaker, Charles B. Tremblay, Jacqueline M. St. Croix, Bradley Seaman, Steven Gonzalez-Pastor, Rebeca Kashentseva, Elena A. Dmitriev, Igor P. Curiel, David T. |
| description | For the developing field of gene therapy the successful address of the basic requirement effective gene delivery has remained a critical barrier. In this regard, the “Holy Grail” vector envisioned by the field's pioneers embodied the ability to achieve efficient and specific in vivo gene delivery. Functional linkage of antibody selectivity with viral vector efficiency represented a logical strategy but has been elusive. Here we have addressed this key issue by developing the technical means to pair antibody-based targeting with adenoviral-mediated gene transfer. Our novel method allows efficient and specific gene delivery. Importantly, our studies validated the achievement of this key vectorology mandate in the context of in vivo gene delivery. Vectors capable of effective in vivo delivery embody the potential to dramatically expand the range of successful gene therapy cures.
[Display omitted] |
| doi_str_mv | 10.1016/j.jconrel.2021.04.009 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_10292108</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0168365921001759</els_id><sourcerecordid>2515689271</sourcerecordid><originalsourceid>FETCH-LOGICAL-c468t-be273f0d585fd2154a5de2b40583515a6d456dfa9c19b332eef8247225d485c93</originalsourceid><addsrcrecordid>eNqFkU9v1DAQxS0EotuWjwDykUuC_ybOCVUVLUiVuNCz5diT1KvEXuwkUvn09apLgRMny5733sz4h9B7SmpKaPNpX-9tDAmmmhFGayJqQrpXaEdVyyvRdfI12hWdqngjuzN0nvOeECK5aN-iM85VyxrW7tDhym0mWHB4hACLtxjC6ANA8mHES8TGPnjYAPuAN79FvJg0Fl0pxgEbByFuPq0Zr4uf_K_juzUzTN7hXC4TYBdnU8wmLL6P7vESvRnMlOHd6bxA9zdfflx_re6-3367vrqrrGjUUvXAWj4QJ5UcHKNSGOmA9YJIxSWVpnFCNm4wnaVdzzkDGBQTLWPSCSVtxy_Q5-fcw9rP4CyEJZlJH5KfTXrU0Xj9byX4Bz3GTVPCOkaJKgkfTwkp_lwhL3r22cI0mQBxzZqVORrVsZYWqXyW2hRzTjC89KFEH3HpvT7h0kdcmghdcBXfh7-HfHH95vNnCyhftXlIOlsPR14-gV20i_4_LZ4A5eCsVg</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2515689271</pqid></control><display><type>article</type><title>Advanced genetic engineering to achieve in vivo targeting of adenovirus utilizing camelid single domain antibody</title><source>MEDLINE</source><source>Elsevier ScienceDirect Journals Complete</source><creator>Lee, Myungeun ; Lu, Zhi Hong ; Shoemaker, Charles B. ; Tremblay, Jacqueline M. ; St. Croix, Bradley ; Seaman, Steven ; Gonzalez-Pastor, Rebeca ; Kashentseva, Elena A. ; Dmitriev, Igor P. ; Curiel, David T.</creator><creatorcontrib>Lee, Myungeun ; Lu, Zhi Hong ; Shoemaker, Charles B. ; Tremblay, Jacqueline M. ; St. Croix, Bradley ; Seaman, Steven ; Gonzalez-Pastor, Rebeca ; Kashentseva, Elena A. ; Dmitriev, Igor P. ; Curiel, David T.</creatorcontrib><description>For the developing field of gene therapy the successful address of the basic requirement effective gene delivery has remained a critical barrier. In this regard, the “Holy Grail” vector envisioned by the field's pioneers embodied the ability to achieve efficient and specific in vivo gene delivery. Functional linkage of antibody selectivity with viral vector efficiency represented a logical strategy but has been elusive. Here we have addressed this key issue by developing the technical means to pair antibody-based targeting with adenoviral-mediated gene transfer. Our novel method allows efficient and specific gene delivery. Importantly, our studies validated the achievement of this key vectorology mandate in the context of in vivo gene delivery. Vectors capable of effective in vivo delivery embody the potential to dramatically expand the range of successful gene therapy cures.
[Display omitted]</description><identifier>ISSN: 0168-3659</identifier><identifier>EISSN: 1873-4995</identifier><identifier>DOI: 10.1016/j.jconrel.2021.04.009</identifier><identifier>PMID: 33872627</identifier><language>eng</language><publisher>Netherlands: Elsevier B.V</publisher><subject>Adenoviral vectors (Ad) ; Adenoviridae - genetics ; Camelid single domain antibody (sdAb) ; CD276 [B7-H3] ; Gene delivery ; Gene Transfer Techniques ; Genetic Engineering ; Genetic Therapy ; Genetic Vectors ; Human epithelial ovarian cancer cell (SKOV3.ip1) ; Ovarian Cancer (OvCa) xenograft mouse model ; Single-Domain Antibodies - genetics</subject><ispartof>Journal of controlled release, 2021-06, Vol.334, p.106-113</ispartof><rights>2021 The Author(s)</rights><rights>Copyright © 2021 The Author(s). Published by Elsevier B.V. All rights reserved.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c468t-be273f0d585fd2154a5de2b40583515a6d456dfa9c19b332eef8247225d485c93</citedby><cites>FETCH-LOGICAL-c468t-be273f0d585fd2154a5de2b40583515a6d456dfa9c19b332eef8247225d485c93</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://dx.doi.org/10.1016/j.jconrel.2021.04.009$$EHTML$$P50$$Gelsevier$$Hfree_for_read</linktohtml><link.rule.ids>230,314,780,784,885,3550,27924,27925,45995</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/33872627$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Lee, Myungeun</creatorcontrib><creatorcontrib>Lu, Zhi Hong</creatorcontrib><creatorcontrib>Shoemaker, Charles B.</creatorcontrib><creatorcontrib>Tremblay, Jacqueline M.</creatorcontrib><creatorcontrib>St. Croix, Bradley</creatorcontrib><creatorcontrib>Seaman, Steven</creatorcontrib><creatorcontrib>Gonzalez-Pastor, Rebeca</creatorcontrib><creatorcontrib>Kashentseva, Elena A.</creatorcontrib><creatorcontrib>Dmitriev, Igor P.</creatorcontrib><creatorcontrib>Curiel, David T.</creatorcontrib><title>Advanced genetic engineering to achieve in vivo targeting of adenovirus utilizing camelid single domain antibody</title><title>Journal of controlled release</title><addtitle>J Control Release</addtitle><description>For the developing field of gene therapy the successful address of the basic requirement effective gene delivery has remained a critical barrier. In this regard, the “Holy Grail” vector envisioned by the field's pioneers embodied the ability to achieve efficient and specific in vivo gene delivery. Functional linkage of antibody selectivity with viral vector efficiency represented a logical strategy but has been elusive. Here we have addressed this key issue by developing the technical means to pair antibody-based targeting with adenoviral-mediated gene transfer. Our novel method allows efficient and specific gene delivery. Importantly, our studies validated the achievement of this key vectorology mandate in the context of in vivo gene delivery. Vectors capable of effective in vivo delivery embody the potential to dramatically expand the range of successful gene therapy cures.
[Display omitted]</description><subject>Adenoviral vectors (Ad)</subject><subject>Adenoviridae - genetics</subject><subject>Camelid single domain antibody (sdAb)</subject><subject>CD276 [B7-H3]</subject><subject>Gene delivery</subject><subject>Gene Transfer Techniques</subject><subject>Genetic Engineering</subject><subject>Genetic Therapy</subject><subject>Genetic Vectors</subject><subject>Human epithelial ovarian cancer cell (SKOV3.ip1)</subject><subject>Ovarian Cancer (OvCa) xenograft mouse model</subject><subject>Single-Domain Antibodies - genetics</subject><issn>0168-3659</issn><issn>1873-4995</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2021</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqFkU9v1DAQxS0EotuWjwDykUuC_ybOCVUVLUiVuNCz5diT1KvEXuwkUvn09apLgRMny5733sz4h9B7SmpKaPNpX-9tDAmmmhFGayJqQrpXaEdVyyvRdfI12hWdqngjuzN0nvOeECK5aN-iM85VyxrW7tDhym0mWHB4hACLtxjC6ANA8mHES8TGPnjYAPuAN79FvJg0Fl0pxgEbByFuPq0Zr4uf_K_juzUzTN7hXC4TYBdnU8wmLL6P7vESvRnMlOHd6bxA9zdfflx_re6-3367vrqrrGjUUvXAWj4QJ5UcHKNSGOmA9YJIxSWVpnFCNm4wnaVdzzkDGBQTLWPSCSVtxy_Q5-fcw9rP4CyEJZlJH5KfTXrU0Xj9byX4Bz3GTVPCOkaJKgkfTwkp_lwhL3r22cI0mQBxzZqVORrVsZYWqXyW2hRzTjC89KFEH3HpvT7h0kdcmghdcBXfh7-HfHH95vNnCyhftXlIOlsPR14-gV20i_4_LZ4A5eCsVg</recordid><startdate>20210610</startdate><enddate>20210610</enddate><creator>Lee, Myungeun</creator><creator>Lu, Zhi Hong</creator><creator>Shoemaker, Charles B.</creator><creator>Tremblay, Jacqueline M.</creator><creator>St. Croix, Bradley</creator><creator>Seaman, Steven</creator><creator>Gonzalez-Pastor, Rebeca</creator><creator>Kashentseva, Elena A.</creator><creator>Dmitriev, Igor P.</creator><creator>Curiel, David T.</creator><general>Elsevier B.V</general><scope>6I.</scope><scope>AAFTH</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>5PM</scope></search><sort><creationdate>20210610</creationdate><title>Advanced genetic engineering to achieve in vivo targeting of adenovirus utilizing camelid single domain antibody</title><author>Lee, Myungeun ; Lu, Zhi Hong ; Shoemaker, Charles B. ; Tremblay, Jacqueline M. ; St. Croix, Bradley ; Seaman, Steven ; Gonzalez-Pastor, Rebeca ; Kashentseva, Elena A. ; Dmitriev, Igor P. ; Curiel, David T.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c468t-be273f0d585fd2154a5de2b40583515a6d456dfa9c19b332eef8247225d485c93</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2021</creationdate><topic>Adenoviral vectors (Ad)</topic><topic>Adenoviridae - genetics</topic><topic>Camelid single domain antibody (sdAb)</topic><topic>CD276 [B7-H3]</topic><topic>Gene delivery</topic><topic>Gene Transfer Techniques</topic><topic>Genetic Engineering</topic><topic>Genetic Therapy</topic><topic>Genetic Vectors</topic><topic>Human epithelial ovarian cancer cell (SKOV3.ip1)</topic><topic>Ovarian Cancer (OvCa) xenograft mouse model</topic><topic>Single-Domain Antibodies - genetics</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Lee, Myungeun</creatorcontrib><creatorcontrib>Lu, Zhi Hong</creatorcontrib><creatorcontrib>Shoemaker, Charles B.</creatorcontrib><creatorcontrib>Tremblay, Jacqueline M.</creatorcontrib><creatorcontrib>St. Croix, Bradley</creatorcontrib><creatorcontrib>Seaman, Steven</creatorcontrib><creatorcontrib>Gonzalez-Pastor, Rebeca</creatorcontrib><creatorcontrib>Kashentseva, Elena A.</creatorcontrib><creatorcontrib>Dmitriev, Igor P.</creatorcontrib><creatorcontrib>Curiel, David T.</creatorcontrib><collection>ScienceDirect Open Access Titles</collection><collection>Elsevier:ScienceDirect:Open Access</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Journal of controlled release</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Lee, Myungeun</au><au>Lu, Zhi Hong</au><au>Shoemaker, Charles B.</au><au>Tremblay, Jacqueline M.</au><au>St. Croix, Bradley</au><au>Seaman, Steven</au><au>Gonzalez-Pastor, Rebeca</au><au>Kashentseva, Elena A.</au><au>Dmitriev, Igor P.</au><au>Curiel, David T.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Advanced genetic engineering to achieve in vivo targeting of adenovirus utilizing camelid single domain antibody</atitle><jtitle>Journal of controlled release</jtitle><addtitle>J Control Release</addtitle><date>2021-06-10</date><risdate>2021</risdate><volume>334</volume><spage>106</spage><epage>113</epage><pages>106-113</pages><issn>0168-3659</issn><eissn>1873-4995</eissn><abstract>For the developing field of gene therapy the successful address of the basic requirement effective gene delivery has remained a critical barrier. In this regard, the “Holy Grail” vector envisioned by the field's pioneers embodied the ability to achieve efficient and specific in vivo gene delivery. Functional linkage of antibody selectivity with viral vector efficiency represented a logical strategy but has been elusive. Here we have addressed this key issue by developing the technical means to pair antibody-based targeting with adenoviral-mediated gene transfer. Our novel method allows efficient and specific gene delivery. Importantly, our studies validated the achievement of this key vectorology mandate in the context of in vivo gene delivery. Vectors capable of effective in vivo delivery embody the potential to dramatically expand the range of successful gene therapy cures.
[Display omitted]</abstract><cop>Netherlands</cop><pub>Elsevier B.V</pub><pmid>33872627</pmid><doi>10.1016/j.jconrel.2021.04.009</doi><tpages>8</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0168-3659 |
| ispartof | Journal of controlled release, 2021-06, Vol.334, p.106-113 |
| issn | 0168-3659 1873-4995 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_10292108 |
| source | MEDLINE; Elsevier ScienceDirect Journals Complete |
| subjects | Adenoviral vectors (Ad) Adenoviridae - genetics Camelid single domain antibody (sdAb) CD276 [B7-H3] Gene delivery Gene Transfer Techniques Genetic Engineering Genetic Therapy Genetic Vectors Human epithelial ovarian cancer cell (SKOV3.ip1) Ovarian Cancer (OvCa) xenograft mouse model Single-Domain Antibodies - genetics |
| title | Advanced genetic engineering to achieve in vivo targeting of adenovirus utilizing camelid single domain antibody |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-27T06%3A51%3A35IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Advanced%20genetic%20engineering%20to%20achieve%20in%20vivo%20targeting%20of%20adenovirus%20utilizing%20camelid%20single%20domain%20antibody&rft.jtitle=Journal%20of%20controlled%20release&rft.au=Lee,%20Myungeun&rft.date=2021-06-10&rft.volume=334&rft.spage=106&rft.epage=113&rft.pages=106-113&rft.issn=0168-3659&rft.eissn=1873-4995&rft_id=info:doi/10.1016/j.jconrel.2021.04.009&rft_dat=%3Cproquest_pubme%3E2515689271%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2515689271&rft_id=info:pmid/33872627&rft_els_id=S0168365921001759&rfr_iscdi=true |